Concepedia

Kerry Keertikar

KK

Statistics

Publications

9

Citations

434

H-Index

9

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Kerry Keertikar is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicinal chemistry, and pharmacy.

Publications per year

2007–2018

9

Publications

9

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez et al. · ACS Medicinal Chemistry Letters · 2010 · 175 citations

, , +10

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1

Michael P. Dwyer, Kamil Paruch, Marc Labroli et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 69 citations

, , +12

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 67 citations · Full text

, , +10

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

Michael P. Dwyer, Kamil Paruch, Carmen Álvarez et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 39 citations

, , +16

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development

Anilkumar G. Nair, Qingbei Zeng, Oleg Selyutin et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 27 citations · Full text

, , +15

1–5 of 9